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Background: Several epidemiological studies from Taiwan, all using the same data resource, 
found significant associations between herpes virus infection, antiherpetic medication and 
subsequent dementia. We conducted a multicenter observational cohort study using health registry 
data from Wales, Germany, Scotland, and Denmark to investigate potential associations between 
antiherpetic medication and incident dementia, and also to comprehensively investigate such 
associations broken down according to medication type and dose, type of herpes virus, and 
dementia subtype.
Methods: 2.5 million individuals aged ≥65 years were followed up using linked electronic health 
records in four national observational cohort studies. Exposure and outcome were classified using 
coded data from primary and secondary care. Data were analyzed using survival analysis with 
time-dependent covariates.
Results: Results were heterogeneous, with a tendency towards decreased dementia risk in 
individuals exposed to antiherpetic medication. Associations were not affected by treatment 
number, herpes subtype, dementia subtype, or specific medication. In one cohort, individuals 
diagnosed with herpes but not exposed to antiherpetic medication were at higher dementia risk.
Conclusion: Short-term antiherpetic medication is not markedly associated with incident 
dementia. Because neither dementia subtype nor herpes subtype modified the association, the 
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1. INTRODUCTION
The role of infections in the development of dementia has been widely debated 1. Attention has 
focused on herpes viruses infection in part because variants at the APOE locus are not only 
associated with Alzheimer’s disease (AD) (e.g., 2) but also govern extent of damage caused by 
infection with herpes viruses (e.g., 3). Moreover, infections with herpes simplex virus (HSV) and 
the related varicella zoster virus (VZV) are known to induce deposition of amyloid-β 4–6.
Several epidemiological studies from Taiwan, all using the same data resource, found 
significant associations between herpes virus infection, antiherpetic medication and dementia. 
First, individuals diagnosed with herpes zoster ophtalmicus (caused by VZV) had an increased 
(HR = 3) rate of incident dementia within 5 years of diagnosis 7; information on antiherpetic 
medication was not available. Second, patients with herpes zoster  infection had a slightly 
increased risk of incident dementia (HR = 1.1) compared to controls 8, and the subgroup who were 
treated with antiherpetic medication had a reduced risk of dementia (HR = 0.6) compared to 
untreated HSV-positive patients. Third, HSV infection was reported to increase the risk of incident 
dementia (HR = 2.5) 9, and treatment with antiherpetic medication markedly reduced the risk (HR 
= 0.1 versus untreated HSV-positive controls). Moreover, the association was greater in those 
treated for longer times. In addition, a study from South Korea reported that patients with VZV 
infection had an increased rate of incident dementia (HR = 1.1), but this was reduced (HR = 0.8 
versus untreated VZV) by antiherpetic medications 10. These results were surprising, given the 
brevity of antiherpetic persistence in the human body.
Despite these reports, a recent meta-analysis into associations of human herpesvirus 
infections with dementia or mild cognitive impairment concluded that evidence to date for an 
association is insufficient 11. 
We therefore conducted a multicenter observational cohort study using health registry data 
from Wales, Germany, Scotland, and Denmark to investigate potential associations between 
antiherpetic medication and incident dementia, and also to comprehensively investigate such 
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2. METHODS
The primary objective was to study the association between oral antiherpetic medication and 
incident dementia. Secondary objectives were to study whether that association was modified by 
(i) number of treatments; (ii) herpes subtype; (iii) type of antiherpetic medication, and (iv) 
dementia subtype.
2.1 Data sources
We utilized linked routinely collected health data (RCHD) from four different sources: (i) the 
Secure Anonymised Information Linkage Databank (SAIL), Wales (1995-2018); (ii) the IMS® 
Disease Analyzer, Germany (1992-2017); (iii) the Danish National Registries (DNR) (2000-2015); 
and (iv) the Electronic Data Research and Innovation Service (eDRIS) of Public Health, Scotland 
(2004-2020). 
The SAIL Databank holds anonymized health data from ~80% of Welsh general practioner 
practices linked to national datasets including inpatient records, death records, and Welsh Index of 
Multiple Deprivation (WIMD) 12. The IMS Disease Analyzer database holds unlinked and 
anonymized information on drug prescriptions, diagnoses, and basic medical and demographic 
data from ~3% of all outpatient medical practices in Germany 13. The DNR comprise linked 
RCHD from the entire Danish population; registers used in this study were the Danish Civil 
Registration System14, the Danish National Patient Registry15, and the Danish National 
Prescription Registry16. The eDRIS database holds countrywide linked anonymous RCHD on 
hospital admissions, prescriptions, mortality, and national health service registration data 17. All 
four datasets are representative of the general population in the relevant country; however, 
individuals with poor quality/missing identifier data or reduced access to healthcare (e.g., 
migrants) are likely to be under-represented.
2.2 Study populations
The study populations in SAIL, IMS Disease Analyzer, and eDRIS comprised all individuals with 
follow-up data from age 60 onwards who had no dementia-related record before their 65th 
birthday, were alive at their 65th birthday, and for whom no information on any of the covariates 
in the analysis was missing (Figure 1). The study population in DNR comprised all individuals 
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start of follow-up. In IMS Disease Analyzer, individuals were excluded for whom a dementia-
related prescription but no dementia-related diagnosis could be found or who received antiherpetic 
medication during follow-up without any known herpes-related diagnosis. Start of follow-up in 
cohorts from SAIL, IMS Disease Analyzer, and eDRIS was the 65th birthday (mid-month in 
datasets where only month and year of birth were available, or mid-year where only year of birth 
was available). In the DNR cohort, start of follow-up was the later  of 1 January 2000 and 65th 
birthday. End of follow-up was at the date of the first dementia-related code or the date of 
deregistration, death, or the end of the study period. In the unlinked data from IMS Disease 
Analyzer, mortality data were not available; however, a death would have been recorded as 
deregistration (Table 1).
2.3. Dementia classification
In all datasets we used coded information to classify individuals with dementia, using the date of 
the first code as date of diagnosis. Table S1 lists codes used for dementia classification. In SAIL, 
individuals were classified as having dementia if they had a dementia-related diagnostic code from 
primary care, hospital admission, or mortality records (underlying or contributing cause). In the 
unlinked data from IMS Disease Analyzer, individuals were classified as having dementia if a 
dementia-related diagnosis was documented from primary care data. In DNR and eDRIS, 
individuals were classified as having dementia if they had a dementia-related prescription or 
dementia-related hospitalization. In cohorts with available diagnostic codes from primary care 
(SAIL and IMS Disease Analyzer), diagnostic codes were also used to subtype dementia into AD, 
vascular dementia (VD), and 'other/unknown'. Individuals with codes for both subtypes were 
counted as both AD and VD ('mixed dementia' is not coded in the RCHD). The positive predictive 
value (PPV) of RCHD (diagnostic codes from primary care, hospitalization, and mortality records) 
to classify dementia and dementia subtypes has recently been studied in Scotland, and the data 
showed good PPV for classification of dementia and AD, but relatively low PPV for classifying 
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2.4 Antiherpetic drugs
In all datasets, exposure to antiherpetic medication was restricted to oral antiherpetic medication; 
topical applications can be purchased without prescription and are therefore under-reported in 
RCHD. Exposure classification was also restricted to prescriptions from primary care because 
those from hospital admissions were not available. However, in all our study populations herpes 
associated hospital admissions were rare events. In the DNR, of the 1,712,100 people in the 
cohort, there were 11,720 people who had any herpes associated hospital admissions during the 
study period. Of these, only 4115 people had herpes associated hospital admissions and never any 
prescriptions.  In all four countries prescriptions from primary or secondary care are necessary for 
access to oral antiherpetic medication; however, medication can be prescribed over the internet, in 
which case exposure would not be recorded in our databases. Table S1 lists codes used for 
antiherpetic medication classification.
2.5 Herpes classification
In SAIL and IMS Disease Analyzer, codes from primary care diagnosis and hospital admissions 
were used to classify herpes infection and herpes subtypes (Herpes simplex and H. zoster), and the 
date of the first diagnostic code was taken as the date of diagnosis. Individuals with diagnostic 
codes for both subtypes were classified according to the diagnostic code entered at first diagnosis 
(diagnostic codes in Table S1). While a large proportion of the general population is subclinically 
infected with herpes virus, people were classified to be infected in our study only if they have had 
a herpes-related diagnosis in primary or secondary care; the diagnosed population therefore 
represents only herpes-infected people with clinical signs severe enough to seek medical help. 
2.6 Covariates
Linked RCHD were used to classify year of birth and sex. We used several proxies for 
socioeconomic status (SES): in SAIL and eDRIS we adjusted for multiple deprivation; in IMS 
Disease Analyzer we adjusted for type of insurance (private insurance being indicative of higher 
disposable income); and in DNR we adjusted for highest education and civil status at start of 
follow-up. In DNR, we additionally adjusted for comorbidities using the Charlson comorbidity 
index (excluding dementia)
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To investigate in SAIL and IMS Disease Analyzer whether the association of antiherpetic 
medication with incident dementia was affected by herpes subtype we conducted a subset analysis 
that included only individuals with either H. zoster infection or without any herpes diagnosis; 
individuals with a diagnosis of H. simplex were excluded. We then repeated the analysis including 
only individuals with H. simplex diagnosis and removed those with H. zoster infection. Co-
infections were not considered. To study the effect of herpes subtype and associated treatment on 
dementia incidence in DNR and eDRIS, individuals were classified by the first prescribed drug 
(only aciclovir) into those with high drug strength (800 mg) and low drug strength (200 or 400 
mg) that are indicative of H. zoster and H. simplex infection according to national prescribing 
guidelines in the two countries.
2.8 Type of dementia
To investigate in SAIL and IMS Disease Analyzer whether the association of antiherpetic 
medication with incident dementia was only seen in a particular type of dementia, we again 
explored a subset of the study population which included only individuals with either a diagnosis 
of AD or without any dementia, and excluded individuals with any other or ‘unknown’ dementia. 
We then repeated the analysis with VD. 
2.9 Type of antiherpetic medication and number of treatments
For medication-specific analysis we included aciclovir and its prodrug, valaciclovir (combined), 
famciclovir (not IMS Disease Analyzer), and brivudine (only IMS Disease Analyzer). The original 
analysis included ganciclovir and valganciclovir; however, we excluded them because very few 
individuals in each cohort received these medications. In eDRIS, from the entire cohort of elderly 
individuals, only 105 received any antiherpetic other than aciclovir or valaciclovir, threfore 
medication-specific analysis was not performed. To study the effect of type of antiherpetic 
medication in SAIL and IMS Disease Analyzer we tested the effect of each drug by excluding 
individuals from the study population who were exclusively exposed to another antiherpetic 
medication. The number of prescriptions (one, two, ≥3) was analysed independently of the time 
between prescriptions. 
2.10 Statistical analysis
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antiherpetic medication were included as time-dependent variables, increasing from zero 
prescriptions (unexposed controls) to ≥3 prescriptions. For cohorts with information on primary 
care diagnosis (SAIL and IMS Disease Analyzer), we additionally included herpes diagnosis as a 
time-dependent variable. In DNR, we used Poisson regression to fit piecewise exponential survival 
models with the logarithm of person years at risk as an offset variable 20(SAS software, Version 
9.4 of the SAS System for Windows). To control for effects of age and year in these models, 
incremental years were included as time-dependent variables. In all other cohorts, we used Cox 
proportional hazard models (R, package survival 21). To control for the effect of calendar year we 
adjusted for birth-year categories; the effects of age were accounted for by following up every 
individual in the cohort from their 65th birthday. For cohorts with information from primary care 
we included the practice number as random effect to control for correlation between patients of the 
same practice (R package coxme22).
2.11 Ethics and Governance
Analysis of data from SAIL and eDRIS was granted under IGRP 0938 and PBPP 1819-0297, 
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3. RESULTS
3.1 Study populations and drug prescription
There was considerable heterogeneity in the composition of the four study populations (Table 1), 
notably in mean follow-up time, ranging from 2.7 years (eDRIS) to 9 years (IMS Disease 
Analyzer). The longer follow-up time was associated with higher proportions of individuals being 
recorded as receiving antiherpetic medication and diagnoses of herpes virus infection and 
dementia. Similarly, including individuals with a start date later than their 65th birthday in DNR 
increased the average age of the DNR cohort and increased the rate of dementia diagnosis and 
death. The proportion diagnosed with herpes viral infection was higher in IMS Disease Analyzer 
than in SAIL, and H. zoster was diagnosed more often than H. simplex in both cohorts. In all four 
cohorts, aciclovir and valaciclovir were the most commonly prescribed antiherpetics; however, in 
IMS Disease Analyzer many prescriptions were for brivudine, a drug that was not prescribed in 
any of the other cohorts. In all four cohorts, antiherpetic medication was most commonly 
prescribed only once during follow-up, and at most 1% of all individuals in the cohorts were 
exposed to three or more doses of any antiherpetic medication. In both cohorts where dementia 
could be subtyped (SAIL and IMS Disease Analyzer) the number of individuals with dementia 
coded as AD was similar to the number coded as VD. In all cohorts, women were more likely to 
be exposed to antiherpetic medication than men (Table S2). Figure S1 in the supplement presents a 
comparison of the different cohorts with the study poulations of Tzeng9 and Bae 22.
3.2 Dementia incidence
 Exposure to one or more doses of antiherpetic medication was significantly associated with a 
slight decrease in dementia incidence in DNR (adjusted hazard ratios ranged from HR = 0.89; 95% 
CI: 0.83–0.95; to HR = 0.93; 95% CI: 0.88–0.98) and in SAIL for a single exposure to 
antiherpetics (aHR=0.91; 95% CI: 0.86-0.97). It was not significantly associated in the other 
cohorts (Figure 2a and Tables S3–S6) Notably, in DNR (the largest cohort included in our study) 
all levels of exposure were associated with a small but significantly reduced incidence of 
dementia. Increased treatment numbers were not associated with differences in effects of exposure 
in any of the cohorts. Adjustment for covariates in the different cohorts did not have a large effect 
on any of the estimated HRs (Tables S3–S6). In IMS Disease Analyzer, individuals diagnosed 
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incidence of dementia compared to those not diagnosed (HR = 1.18; 95% CI: 1.09–1.28) (Figure 
2a and Table S4). This increased rate was not seen in the other cohort that had information on 
diagnosis (SAIL) where individuals diagnosed but not treated had a non-significant lower 
incidence (HR = 0.95; 95% CI: 0.88–1.02) (Figure 2a and Table S3). 
In all cohorts, effects of exposure to antiherpetic medications was independent of medication type 
(Figure 2d). In IMS Disease Analyzer individuals diagnosed with H. zoster and not exposed to any 
antiherpetic medication had a higher rate of dementia (HR = 1.2; 95% CI 1.06–1.35) compared to 
those undiagnosed, whereas dementia incidence in those diagnosed with H. simplex and not 
exposed was unchanged (HR = 0.97; 95% CI 0.88–1.07) (Figure 2c). This trend towards higher 
HRs in individuals diagnosed with H. zoster, and lower HRs in those diagnosed with H. simplex, 
could also be observed in people exposed to antiherpetic medication; however, these differences 
were not significant. In SAIL and DNR, herpes subtype had no effect on the association between 
exposure to antiherpetic medication and dementia. Finally, in both SAIL and IMS Disease 
Analyzer the association between exposure to antiherpetic medication and dementia incidence was 
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DISCUSSION
We analyzed associations between antiherpetic medication and dementia incidence in four large 
national observational cohorts. We report evidence for a low negative association between 
exposure and outcome; however, results were heterogeneous.
The negative association could be related to genuine protective effects of antiherpetic 
medication against neuropathologic consequences of herpes infection. Indeed, in IMS Disease 
Analyzer, individuals diagnosed with herpes infection but not treated were at higher risk of 
dementia compared to both those undiagnosed and those diagnosed with H. zoster and treated. 
This result resembles observations from Taiwan and South Korea 7,9,10. However, there is evidence 
against this interpretation. First, the effect could not be seen in SAIL, the only other cohort with 
available diagnostic information. Second, the associations between antiherpetic medication and 
dementia in SAIL and IMS Disease Analyzer were for both AD and VD, diseases that have 
different neuropathological manifestations. Finally, the association was independent of the herpes 
subtype (H. simplex versus H. zoster), whereas possible associations of herpes infection with 
dementia have mostly been described for H. simplex and less for H. zoster 11. 
Given that in cohorts other than IMS Disease Analyzer we did not see a dose–response 
effect, a direct neuroprotective effect of the antiherpetic medication seems unlikely. However, the 
great majority of patients in all four cohorts received single prescriptions of antiherpetic 
medications (typically for administration over a period of 1–2 weeks), and we cannot exclude the 
possibility that longer-term exposure might have greater effects.
The small negative association could also be related to indirect effects of exposure to 
antiherpetic medication. Given the nature of the observational cohorts, we could not study whether 
associations were affected by APOE genotype. Indeed, because a specific variant at the APOE 
locus, ε4 (APOE4), is associated with susceptibility to both dementia and herpes virus infection, a 
positive association between dementia, herpes infection and antiherpetic medication would be 
expected. Of note, the Danish population in general has a slightly higher proportion of APOE4 
carriers than the other populations 24, which might have contributed to the observed heterogeneity.
Finally, the observed negative association could reflect residual confounding, reverse 
causation, and misclassification. There is clear evidence in all our study populations of a negative 
association between socioeconomic status (SES) and dementia incidence. SES could also be 
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in the statistical models did not change the estimated HR (Tables S3–S6). Similarly, controlling 
for the effects of comorbidities in DNR did not modify the significant negative association 
between exposure and dementia incidence (Table S5). Control for comorbidities is problematic 
because a considerable number of co-morbidities of dementia are early signs of dementia; by 
‘controlling’ for the effect of these, we risk losing the true effect of antiherpetic medication. 
Additionally, the effects of co-morbidities are time-dependent; those increasing the risk to be 
diagnosed with herpes (for example with shingles) infection but are not associated independently 
to dementia should not be considered as confounders.   Vaccination against VZV (shingles 
vaccine) has been reported to be associated with reduced dementia incidence 26. However, the 
major effect of VZV vaccination would be to reduce herpes diagnosis and thereby exposure to 
antiherpetic medication, and therefore vaccination would not act as a confounder in our study. If 
preclinical dementia were to be associated with an increased risk of herpes diagnosis and 
antiherpetic medication, we would have falsely attributed the dementia diagnosis to the 
antiherpetic medication (reverse causation). This would mean that the true negative association 
was slightly larger than the observed HR. However, only <5% of all first antiherpetic medications 
were prescribed <6 months before dementia diagnosis. Finally, individuals in all cohorts might 
have been misclassified as unmedicated if they had received antiherpetic medication purchased 
outside the national public health system. However, our study population was restricted to the 
elderly population (65+), and we feel that exposure misclassification is less likely to have been 
significant.
Some of the heterogeneity could be explained by differences in study design and study 
populations. In DNR and eDRIS the non-exposed cohorts included diagnosed but untreated 
individuals; in the other cohorts these were included as a separate group. Including a mixture of 
diagnosed and untreated individuals and those undiagnosed and untreated could mask a true 
negative association if the association between herpes infection and incident dementia holds true: 
the risk of dementia would be unequal in the exposed and unexposed groups in these cohorts 
(DNR and eDRIS) in our study. By contrast, we have no explanation for the (non-significant) 
trend towards increased dementia risk in individuals exposed to antiherpetic medication in IMS 
Disease Analyzer. Interestingly, the proportion of individuals diagnosed with herpes as well as the 
proportion who were treated was much higher in IMS Disease Analyzer than in SAIL, even 
though individuals in the two cohorts were followed up for similar periods. Although brivudine 
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aciclovir/valaciclovir, and it seems unlikely that the type of antiherpetic medication might explain 
the heterogeneity. Heterogeneity in study design and populations could also explain the 
differences between our results and those from studies from Taiwan and South Korea. Length of 
antiherpetic treatment was significantly longer in the study from 9. However, that study also found an 
approximately 40% reduction in subsequent dementia development for subjects receiving 
medications for less than 30 days, which is not in line with our results. In addition, while we did 
not have direct information on the length of treatment, we did analyse the effect of the number of 
treatments (1,2 and ≥3) and found no trend in greater effect in those exposed to higher number of 
treatments. Number of treatments and treatement duration are not directly comparable; however, 
patients with repeated prescriptions tend to be those with longer treatment durations. Because 
Tzeng et al (2018) 9 classified patients HSV-positive only if they have had ≥3 outpatient visits within 
one calendar year, patients classified as herpes positive in our study might have been different in regard 
to severity of symptoms.
Studies on dementia etiology require large study populations that are followed up over 
long periods of later life. Our study benefitted from the high quality of RCHD in the four nations 
containing reliable information on exposure, outcome, and covariates for a total of >2.5 million 
individuals aged >65 years. The size of the study populations allowed us to control for the single 
most important risk factor for dementia, age, by using a common age at the start of follow-up 
(IMS Disease Analyzer, SAIL, and eDRIS) or by using age as a time-dependent variable (DNR); 
in addition, we were able to include both repeated exposure to antiherpetic medication and herpes 
diagnosis as time-dependent covariates. However, our study has some limitations. Disease and 
exposure classification were based on imperfect information, especially regarding the validity of 
dementia subtypes, and the classification of herpes subtypes using drug strength as a proxy (in 
DNR). However, we would not expect misclassification to be differential. More importantly, 
because only information on the dates of dementia diagnosis and/or first dementia drug exposure 
were available, we could not ascertain whether exposure preceded or followed dementia 
development. Indeed, in the case of AD the pathology is likely to be present >10 years before 
symptom onset, so follow up time in our cohorts would have been insufficient. We could have 
excluded individuals with exposures to antiherpetic medication some period prior to dementia 
diagnosis; nevertheless, any time period would have been arbitrary and follow-up times in 
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In conclusion, results from four large national cohorts indicate that short-term antiherpetic 
medication is not markedly associated with reduced subsequent dementia incidence. Because 
neither type of dementia nor type of herpes infection modified the association, the small but 
significant decrease in dementia incidence with antiherpetic administration may reflect 
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Figure 1 Flow chart of the four study populations.
Figure 2 Association of exposure to antiherpetic medication with dementia incidence in four 
national cohorts (adjusted Hazard ratio and 95% CI). D-T-=not diagnosed, not treated; D+T- = 
diagnosed, not treated; D+T+ = diagnosed and treated once; D+T++ = diagnosed and treated 
twice; D+T+++= diagnosed and treated thrice or more often. (a) Primary outcome (Note the 
different scale of the x-axis for eDRIS compared to the other cohorts.); (b) by dementia subtype 
(AD=Alzheimer’s disease, VD=Vascular Dementia); (c) by herpes subtype; (d) by medication 
type.
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 SAIL Disease Analyzer DNR eDRIS 
Total N (PY
1
) 434,689 (3,255,540) 53,629 (550,852) 1,712,100 (13,798,349) 342,637 (961,666) 
Follow-up in PY, median (IQR
2
) 6.7 (3.3-11.3)  8.8 (4.5-14.5) 7.4 (3.8-12.2) 2.7 (1.4-4.2) 
Deaths N (%) 73,802 (17%) NA
3
 600,610 (35%) 14,994 (4%) 







(1950-1953) Sex     
Female 220,539 (51%) 29,031 (54%) 925,393 (54%) 171,022 (50%) 
Herpes diagnosis    
Total N 53,981(12%) 19,650 (37%) NA NA 








) NA NA 








) NA NA 
Antiherpetic medication
6
    








) 169,989 (8%) 8625 (3%) 
T+ 33,395 (8% / 83%) 8,603 (16% / 83%) 106,185 (6% / 76%) 7336 (2% / 85%) 
T++ 3725 (1% / 9%) 1,151 (2% / 11%)                                             22,476 (1% / 13%) 678 (0.2% / 8%) 
T+++ 2877 (1% / 7%) 598 (1% / 6%) 20,664 (1% / 12%) 581 (0.2% / 7%) 
Acyclovir and valacyclovir 35,940 (8%) 6173 (12%) 167,633 (8%) 8453 (2%) 
Famciclovir 4720 (1.1%) NA 3096 (0.14%) 172 (0.05%) 
Brivudine NA 4140 (8%) NA NA 
Dementia
7
     
Total N (rate) 15,640 (48) 4244 (77) 129,662 (94) 1314 (14) 
AD N (rate) 6607 (21) 767 (18) NA NA 
VD N (rate) 5020 (16) 1024 (23) NA NA 
Age at first diagnosis, median (IQR) 75 (71-79) 74 (69-78) 82 (77-87) 67 (66-68) 
 




 Interquartile range 
3
 In Disease Analyzer, death was recorded as end-of-follow up; including other reasons such as de-registration. 
4
 Percentage of the total study population 
5
 Percentage of those diagnosed 
6
 Number of treatments: T+=treated once; T++=treated twice; T+++=treated thrice or more often 
7










People born in or before 1950, 
alive and in Denmark at age 65 
years or on 1 January 2000 
The Disease Analyzer The Electronic Data Research and 
Innovation Service of Public Health 
eDRIS 
The Secure Anonymised 
Information Linkage 
SAIL 
Danish National Registers 
DNR 
People with available follow up data from age 60 years and onwards, alive at age 65 years 
N=54,814 N=342,637 N=443,518 
N= 53,629  N= 342,039 N= 434,689  N= 1,712,100 
N= 1,739,288 
- People with dementia related RCHD before age 65 years (DNR: or before 1 January 2000). 
- The Disease Analyzer: People with dementia related prescription data but no dementia diagnosis data.  
People with anti-herpetic medication data but no herpes diagnosis data. 
- People with missing covariate data (Not DNR). 
Exclusion criteria: 
Germany  Scotland Wales Denmark 
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